Navigation Links
Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute
Date:3/12/2010

WOODCLIFF LAKE, N.J., March 12 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute (Headquarters: Baltimore, Maryland, Director: John Griffin, M.D., "BSI") related to Eisai's GCPII (glutamate carboxypeptidase II) technology.  

Under the terms of the agreement, Eisai has granted BSI non-exclusive U.S. rights to utilize Eisai's GCPII technology to generate GCPII inhibitor molecules for diseases of the central nervous system, including peripheral neuropathy, Alzheimer's disease, stroke, ALS, neurodegeneration and other disorders in humans.  BSI will be responsible for the research and preclinical development activities.  Eisai will have an exclusive option to license molecules generated using the GCPII technology.

"Johns Hopkins brings significant expertise to Eisai's GCPII inhibitor project," said Lynn Kramer, M.D., President, Neuroscience Product Creation Unit at Eisai.  "Our collaboration may lead to a deeper understanding of diseases of the central nervous system and ultimately to the development of innovative new therapies to address unmet medical needs."      

Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com.

*On October 1, 2009, Eisai Research Institute of Boston, Inc. (established in 1987) and Eisai Medical Research Inc. (established in 2002) were merged into Eisai Inc.

SOURCE Eisai Inc.

Back to top

RELATED LINKS
http://www.eisai.com

'/>"/>

SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Inc. and the Alzheimers Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimers Disease
2. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Diabetics Twice as Likely to Have Hearing Loss; California HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
7. Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
8. Diabetics Twice as Likely to Have Hearing Loss; New Jersey HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
9. Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
10. Diabetics Twice as Likely to Have Hearing Loss; Michigan HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
11. Diabetics Twice as Likely to Have Hearing Loss; Pennsylvania HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 A coalition ... International Development (USAID), the W.K. Kellogg Foundation and ... the Saint Boniface Haiti Foundation (SBHF) last week ... Port-au-Prince . The partnership provides ... Pou Amelyore Ekipman Medikal (REPARE) program, enabling the ...
(Date:1/24/2017)... , Jan. 24, 2017 Italy Ultrasound Systems Market ... ... Market Outlook to 2022", provides key market data on the ... of US dollars, volume (in units) and average prices (USD) ... Real-Time 3D/4D Ultrasound Systems and Hand Held Ultrasound (HHU) Systems. ...
(Date:1/24/2017)... 24, 2017 Asia-Pacific Bone Densitometers Market ... report, "Asia-Pacific Bone Densitometers Market Outlook to 2022", ... Densitometers market. The report provides value, in millions ... prices (USD) within market segements - Dual Energy ... The report also provides company shares and distribution ...
Breaking Medicine Technology:
(Date:1/24/2017)... , ... January 24, 2017 , ... A fifth-year speaker ... of Cypress Benefit Administrators, will return to present about the state of the Affordable ... a “Benefits Adventure” theme this year – will be hosted at Disney’s Grand Californian ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... New York, New York (PRWEB) , ... January 24, 2017 , ... ... demand for Brazilian butt lifts is on the rise. According to the American ... buttock augmentations since 2000. On average, these procedures are performed every 30 minutes of ...
(Date:1/24/2017)... Bethesda, MD (PRWEB) , ... January 24, 2017 ... ... Medical Informatics Association (AMIA) commended the Patient-Centered Outcomes Research Institute (PCORI) for developing ... informaticians suggested that PCORI consider requiring a preliminary data sharing plan as part ...
(Date:1/24/2017)... ... January 24, 2017 , ... To answer the growing demand ... Companies, has designated The Deco a 55 and over residence. ... older in no less than 80% of occupied units. The Deco’s 114 apartments are ...
Breaking Medicine News(10 mins):